CN103998052B - 用于治疗疾病和紊乱的肽类似物 - Google Patents

用于治疗疾病和紊乱的肽类似物 Download PDF

Info

Publication number
CN103998052B
CN103998052B CN201280062729.0A CN201280062729A CN103998052B CN 103998052 B CN103998052 B CN 103998052B CN 201280062729 A CN201280062729 A CN 201280062729A CN 103998052 B CN103998052 B CN 103998052B
Authority
CN
China
Prior art keywords
oral
seq
peptide
sct
glucose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201280062729.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN103998052A (zh
Inventor
诺泽·M·梅赫塔
威廉·斯特恩
艾米·M·施蒂默尔
莫滕·阿塞尔·卡尔斯达尔
基姆·亨里克森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Guanjian Biological Science Co Ltd
Original Assignee
Guanjian Biological Science Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guanjian Biological Science Co Ltd filed Critical Guanjian Biological Science Co Ltd
Publication of CN103998052A publication Critical patent/CN103998052A/zh
Application granted granted Critical
Publication of CN103998052B publication Critical patent/CN103998052B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/585—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
CN201280062729.0A 2011-11-02 2012-11-02 用于治疗疾病和紊乱的肽类似物 Expired - Fee Related CN103998052B (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201161554771P 2011-11-02 2011-11-02
US61/554,771 2011-11-02
US201161578620P 2011-12-21 2011-12-21
US61/578,620 2011-12-21
PCT/US2012/063332 WO2013067357A1 (en) 2011-11-02 2012-11-02 Peptide analogs for treating diseases and disorders
US13/667,578 2012-11-02
US13/667,578 US9006172B2 (en) 2011-11-02 2012-11-02 Peptide analogs for treating diseases and disorders

Publications (2)

Publication Number Publication Date
CN103998052A CN103998052A (zh) 2014-08-20
CN103998052B true CN103998052B (zh) 2016-08-17

Family

ID=48192827

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280062729.0A Expired - Fee Related CN103998052B (zh) 2011-11-02 2012-11-02 用于治疗疾病和紊乱的肽类似物

Country Status (10)

Country Link
US (1) US9006172B2 (enExample)
JP (3) JP6170933B2 (enExample)
KR (1) KR102019911B1 (enExample)
CN (1) CN103998052B (enExample)
AU (2) AU2012332265B2 (enExample)
BR (1) BR112014010701A2 (enExample)
CA (1) CA2854175A1 (enExample)
MX (1) MX351092B (enExample)
RU (1) RU2616511C2 (enExample)
WO (1) WO2013067357A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9533022B2 (en) * 2011-11-02 2017-01-03 KeyBioscience A/S Peptide analogs for treating diseases and disorders
AU2014350328B2 (en) 2013-11-14 2018-04-05 Keybioscience Ag Calcitonin mimetics for treating diseases and disorders
GB201500263D0 (en) * 2015-01-08 2015-02-25 Keybioscience Ag Calcitonin analogues for treating diseases and disorders
GB201704429D0 (en) 2017-03-21 2017-05-03 Keybioscience Ag Calcitonin mimetics for treating diseases and disorders
GB201707955D0 (en) 2017-05-18 2017-07-05 Keybioscience Ag Dual amylin and calcitonin receptor agonists for treating diseases and disorders
GB201813677D0 (en) 2018-08-22 2018-10-03 Keybioscience Ag Calcitonin mimetics for treating diseases and disorders
GB201813678D0 (en) 2018-08-22 2018-10-03 Keybioscience Ag Acylated calcitonin mimetics
US11634095B2 (en) 2020-04-21 2023-04-25 Mac LTT, Inc. Removable safety bar for creating a remote safety visual device
US11420525B2 (en) 2020-04-21 2022-08-23 Mac LTT, Inc. Tractor trailer with included battery charging
US12415457B2 (en) 2020-04-21 2025-09-16 Mac LTT, Inc. Safety zone with breakaway for use on a tanker truck

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1105726C (zh) * 1998-05-15 2003-04-16 中国科学院上海生物化学研究所 人降钙素类似物
WO2010103045A1 (en) * 2009-03-12 2010-09-16 Nordic Bioscience A/S Treatment of diabetes and metabolic syndrome

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6033478B2 (ja) * 1980-06-20 1985-08-02 帝国臓器製薬株式会社 ペプチドの製造方法
US4708934A (en) 1984-09-27 1987-11-24 Unigene Laboratories, Inc. α-amidation enzyme
US6319685B1 (en) 1984-09-27 2001-11-20 Unigene Laboratories, Inc. Alpha-amidating enzyme compositions and processes for their production and use
US4659804A (en) * 1984-11-01 1987-04-21 Armour Pharmaceutical Company (Bis-1,7-S-acetamidomethyl-L-cysteine)salmon calcitonin
US4764589A (en) * 1987-05-26 1988-08-16 Rorer Pharmaceutical Corporation [N-alpha-acyl,8-glycine, des-19-leucine]-calcitonin
US5789234A (en) 1987-08-14 1998-08-04 Unigene Laboratories, Inc. Expression systems for amidating enzyme
US5175146A (en) 1989-12-05 1992-12-29 Vical, Inc. Synthetic calcitonin peptides
US5102666A (en) 1990-09-11 1992-04-07 Oramed, Inc. Calcium polycarbophil controlled release composition and method
US5527790A (en) 1991-09-30 1996-06-18 The University Of British Columbia Bis(maltolato)oxovanadium compositions for the treatment of elevated blood sugar
US5359030A (en) 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
US6692766B1 (en) 1994-06-15 2004-02-17 Yissum Research Development Company Of The Hebrew University Of Jerusalem Controlled release oral drug delivery system
JPH083196A (ja) 1994-06-21 1996-01-09 Sanwa Kagaku Kenkyusho Co Ltd カルシトニン誘導体及びその用途
DE726075T1 (de) 1995-02-08 1996-12-12 Therapicon Srl Nicht-inorganische pharmazeutische salzige Lösungen zur endonasale Verabreichung
US5866536A (en) 1995-03-31 1999-02-02 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5739106A (en) 1995-06-07 1998-04-14 Rink; Timothy J. Appetite regulating compositions
AU6709596A (en) 1995-08-22 1997-03-19 Japan Tobacco Inc. Amide compounds and use of the same
US5962270A (en) * 1996-02-06 1999-10-05 Bionebraska, Inc. Recombinant preparation of calcitonin fragments and use thereof in the preparation of calcitonin and related analogs
US5912014A (en) 1996-03-15 1999-06-15 Unigene Laboratories, Inc. Oral salmon calcitonin pharmaceutical products
US5773647A (en) 1997-02-07 1998-06-30 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
EP2088188B1 (en) 1997-04-16 2011-08-31 Unigene Laboratories, Inc. Direct expression of peptides into culture media
WO2000033866A1 (en) 1998-12-04 2000-06-15 Provalis Uk Limited Pharmaceutical compositions containing insulin
JP2000290295A (ja) 1999-03-31 2000-10-17 Asahi Chem Ind Co Ltd Ｎ−アセチルグルコサミニルカルシトニン
CA2369591C (en) * 1999-04-05 2011-06-14 Emisphere Technologies, Inc. Disodium salts, monohydrate, and ethanol solvates
US6780846B1 (en) 1999-09-27 2004-08-24 Elan Corporation, Plc Membrane translocating peptide drug delivery system
GB2368792A (en) 2000-10-06 2002-05-15 Roger Randal Charles New Absorption enhancers
US6673574B2 (en) 2000-11-30 2004-01-06 Unigene Laboratories Inc. Oral delivery of peptides using enzyme-cleavable membrane translocators
US7316819B2 (en) 2001-03-08 2008-01-08 Unigene Laboratories, Inc. Oral peptide pharmaceutical dosage form and method of production
GB0109438D0 (en) * 2001-04-17 2001-06-06 Isis Innovation Peptides
US6770625B2 (en) 2001-09-07 2004-08-03 Nobex Corporation Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith
JP2006521366A (ja) 2003-03-28 2006-09-21 シグモイド・バイオテクノロジーズ・リミテッド シームレスマイクロカプセルを含む固形経口剤形
GB0308732D0 (en) 2003-04-15 2003-05-21 Axcess Ltd Absorption enhancers
TWI343816B (en) 2003-07-23 2011-06-21 Novartis Ag Use of calcitonin in osteoarthritis
US20070172517A1 (en) 2003-09-17 2007-07-26 Ben-Sasson Shmuel A Compositions capable of facilitation penetration across a biological barrier
ATE471340T1 (de) 2004-02-11 2010-07-15 Amylin Pharmaceuticals Inc Peptide der amylin familie, verfahren zu deren herstellung und verwendung
US7399744B2 (en) 2004-03-04 2008-07-15 Amylin Pharmaceuticals, Inc. Methods for affecting body composition
WO2006008270A1 (de) 2004-07-22 2006-01-26 Thiomatrix Forschungs- Und Beratungs Gmbh Verwendung von thiolgruppen-hältigen verbindungen als efflux-pumpen-hemmer
GB0422644D0 (en) * 2004-10-12 2004-11-10 Novartis Ag Organic compounds
US8394765B2 (en) 2004-11-01 2013-03-12 Amylin Pharmaceuticals Llc Methods of treating obesity with two different anti-obesity agents
US7445911B2 (en) 2004-11-24 2008-11-04 Unigene Laboratories Inc. Enzymatic reactions in the presence of keto acids
WO2007002532A2 (en) 2005-06-24 2007-01-04 Unigene Laboratories, Inc. Cell lines for expressing enzyme useful in the preparation of amidated products
US9259456B2 (en) 2005-09-06 2016-02-16 Oramed Pharmaceuticals Inc. Methods and compositions for oral administration of proteins
US8093207B2 (en) 2005-12-09 2012-01-10 Unigene Laboratories, Inc. Fast-acting oral peptide pharmaceutical products
PL1834635T3 (pl) 2006-03-13 2012-01-31 Advancell Advanced In Vitro Cell Tech S A Stabilne układy nanokapsułek do podawania cząsteczek aktywnych
CA2648594C (en) 2006-04-07 2012-10-16 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
US8377863B2 (en) 2007-05-29 2013-02-19 Unigene Laboratories Inc. Peptide pharmaceutical for oral delivery
US8962015B2 (en) 2007-09-28 2015-02-24 Sdg, Inc. Orally bioavailable lipid-based constructs
CN102292346B (zh) * 2009-01-22 2015-12-02 关键生物科学有限公司 肥胖的治疗

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1105726C (zh) * 1998-05-15 2003-04-16 中国科学院上海生物化学研究所 人降钙素类似物
WO2010103045A1 (en) * 2009-03-12 2010-09-16 Nordic Bioscience A/S Treatment of diabetes and metabolic syndrome

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
重组降钙素研究进展;戴光荣;《医学研究生学报》;20051031;第18卷(第10期);953-955 *
鲑降钙素类似物[Glu31, Pro32-N(C2H5)2]sCT的合成、二级结构及活性研究;杨彬;《军事医学科学院院刊》;19971231;第21卷(第4期);247-250 *

Also Published As

Publication number Publication date
JP2014532722A (ja) 2014-12-08
MX351092B (es) 2017-10-02
WO2013067357A1 (en) 2013-05-10
JP6330013B2 (ja) 2018-05-23
US9006172B2 (en) 2015-04-14
JP6170933B2 (ja) 2017-07-26
JP2017061500A (ja) 2017-03-30
KR102019911B1 (ko) 2019-09-09
AU2012332265B2 (en) 2016-11-10
JP6547034B2 (ja) 2019-07-17
JP2018135360A (ja) 2018-08-30
AU2012332265A1 (en) 2014-06-05
AU2016247189B2 (en) 2017-09-14
CA2854175A1 (en) 2013-05-10
MX2014005265A (es) 2014-10-13
AU2016247189A1 (en) 2016-11-10
RU2616511C2 (ru) 2017-04-17
RU2014122171A (ru) 2015-12-10
CN103998052A (zh) 2014-08-20
KR20140093967A (ko) 2014-07-29
US20130183385A1 (en) 2013-07-18
BR112014010701A2 (pt) 2020-06-23
NZ625215A (en) 2016-04-29

Similar Documents

Publication Publication Date Title
CN103998052B (zh) 用于治疗疾病和紊乱的肽类似物
CN105722854B (zh) 用于治疗疾病和病症的降钙素模拟物
US10239929B2 (en) Peptide analogs for treating diseases and disorders
EP2773365B1 (en) Peptide analogs for treating diseases and disorders
JP2020511479A (ja) 疾患および障害を治療するためのカルシトニン模倣体
WO2018211111A1 (en) Dual amylin and calcitonin receptor agonists for treating diseases and disorders
WO2020039052A1 (en) Calcitonin mimetics for treating diseases and disorders
NZ625215B2 (en) Peptide analogs for treating diseases and disorders
HK1247623B (en) Calcitonin mimetics for treating diseases and disorders
HK1227415B (en) Calcitonin mimetics for treating diseases and disorders
HK1227415A1 (en) Calcitonin mimetics for treating diseases and disorders

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20160817

Termination date: 20191102

CF01 Termination of patent right due to non-payment of annual fee